Inventiva (NASDAQ:IVA) Shares Gap Up Following Analyst Upgrade

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) gapped up before the market opened on Wednesday after UBS Group upgraded the stock to a strong-buy rating. The stock had previously closed at $4.54, but opened at $4.85. Inventiva shares last traded at $4.8560, with a volume of 235,988 shares changing hands.

Other analysts have also recently issued research reports about the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Inventiva in a report on Wednesday, October 8th. Guggenheim lowered their price target on shares of Inventiva from $13.00 to $11.00 and set a “buy” rating on the stock in a report on Tuesday, November 18th. Wolfe Research upgraded shares of Inventiva to a “strong-buy” rating in a research report on Thursday, November 6th. Wall Street Zen raised shares of Inventiva to a “hold” rating in a report on Saturday, October 18th. Finally, Canaccord Genuity Group reissued a “buy” rating and issued a $20.00 price target on shares of Inventiva in a report on Tuesday, September 30th. Two investment analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $16.57.

Institutional Investors Weigh In On Inventiva

Several hedge funds have recently bought and sold shares of the stock. Creative Planning purchased a new position in Inventiva in the 2nd quarter worth approximately $32,000. Wealth Enhancement Advisory Services LLC grew its position in Inventiva by 54.5% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 16,558 shares of the company’s stock worth $50,000 after acquiring an additional 5,843 shares in the last quarter. NewEdge Advisors LLC purchased a new position in Inventiva in the third quarter worth $116,000. Finally, Millennium Management LLC bought a new position in Inventiva in the third quarter valued at $649,000. 19.06% of the stock is currently owned by institutional investors.

Inventiva Stock Performance

The stock has a 50-day simple moving average of $4.31 and a two-hundred day simple moving average of $4.45.

Inventiva Company Profile

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.